<div id="readability-page-1">CraniUS Therapeutics LLC, a private neurotechnology company, recently disclosed that it has secured $20 million in Series B funding. This substantial amount is intended to expedite the advancement of NeuroPASS™, a groundbreaking project designed to enable direct therapeutic access beyond the blood-brain barrier.</div>

FULC

<p>CraniUS Therapeutics LLC, a private neurotechnology company, recently disclosed that it has secured $20 million in Series B funding. This substantial amount is intended to expedite the advancement of NeuroPASS™, a groundbreaking project designed to enable direct therapeutic access beyond the blood-brain barrier.</p>

Unusual Whales

Fulcrum Therapeutics

iShares US Pharma

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

iShares Global Healthcare

VG Health

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

CNS Pharma

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

CraniUS Therapeutics secures $20M in Series B funding for NeuroPASS™ platform development to penetrate blood-brain barrier.